Debate: Should Low Risk PV-MF Patients be Treated?
Treatment of low-risk patients with polycythemia vera (PV) and myelofibrosis (MF) is still a matter of debate. Although traditionally these patients were managed exclusively with supportive treatment, more recent guidelines suggest the opportunity of identifying subgroups of patients eligible for cytoreduction.
In this debate recorded during the EHA22 Annual Congress, experts Claire Harrison and Christen Lykkegaard Andersen support opposite statements on this topic, discussing the pros and cons of cytoreductive treatment in low-risk PV and MF patients, with the aid of representative clinical…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.